About this course

Allergic diseases, a global health concern, have remarkably increased in the last decade, with more than 30% of the population affected by one or more allergic diseases. Not all patients respond to the array of treatment of IgE-mediated chronic diseases like antihistamines, corticosteroids and other anti-inflammatory medications. To target IgE, biological drugs have been pursued in the treatment of severe cases. The currently available anti-IgE agent, omalizumab is the only biological drug licensed as an adjunctive therapy in children aged > 6 years with moderate-to-severe and severe allergic asthma uncontrolled after treatment with high dose of inhaled corticosteroids (ICS) plus long-acting inhaled β2-agonists (LABA).

Benefits for learners

• Continued professional development and learning.
• Better understanding on role of anti IgE in paediatric allergic diseases.
• Certification of recognition from the reputed Society/Association/University.

Intended Audience

Healthcare professionals involved in managing Paediatric Allergic diseases are eligible for this course, especially those working in isolated or remote settings with limited access to the latest evidence-based information.

Learning objectives

At the end of this activity the participant is likely to understand:

• The pathophysiology of allergies in paediatric age group.
• Role of anti-IgE therapies in paediatric allergic disease.
• Clinical trials in omalizumab in paediatric allergies.

Accreditation Statement

This activity is organized by Insignia Communication Ltd.

Physician Accreditation Statement

Accreditation is pending.

Educational Grant

This educational activity is independently produced by Insignia Communications.

Method of Participation

Participants should first read the objectives and other introductory CME information and then proceed to the educational activity. If a pre- and post-test is required to receive credit for this activity, participants must complete the post-test and then complete the evaluation.

Certificate

Participants will gain a certificate of completion from the reputed Society/Association/University.

Completion Certificate

Upon completing all modules and assessments, you will receive an e-certificate, recognizing your achievement.

Course Development details

The following faculty stated they have no financial relationships with ineligible companies:

• Dr. Shwetal Sanghvi (MBBS, DLO, DORL, FCPS)
• Ms Aditi Munghate, Insignia Communications Planner, stated she has no financial relationships with ineligible companies.

To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a Clinical Content Review Committee which has nothing to disclose. The resulting certified activity was found to provide educational content that is current and evidence-based to protect learners from commercial bias and marketing.

Off-label Statement

This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Insignia Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject.